 This study introduces a novel liposomankate teraparitide, PTH, 1-34, incorporated into a Gallic acid grafted gelatin injectable Hydrogel, GLP Hydrogel, to improve the delivery of PTH, 1-34, for the treatment of osteoarthritis OA. The GLP Hydrogel was found to be capable of forming in situ and without affecting the motion after intraarticular injection in mice. It also demonstrated controlled, sustained release of PTH, 1-34, from the GLP Hydrogel. Furthermore, the GLP Hydrogel promoted ATDC5 cell proliferation and protected the Illinois, one induced ATDC5 cells from further OA progression by regulating the PI3K-AKT signaling pathway. Finally, intraarticular injection of Hydrogels into an OA-induced mouse model promoted glycosaminoglycan synthesis and protected the cartilage from degradation, suggesting its potential as a biomaterial for OA treatment. This article was authored by Gua Qingli, Sulu, Yixiaochen, and others. We are article.tv, links in the description below.